Henry  Mosberg

Prof. Dr. Henry Mosberg

Tom D. Rowe Professor of Medicinal Chemistry, Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2011 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
ALAndrei L. Lomize
Andrei L. Lomize
IPIrina D. Pogozheva
Irina D. Pogozheva
Henry  MosbergHenry Mosberg
Henry Mosberg

1 January 2007 in BMC Structural Biology
Verified
Journal Article
Open access
PDF file
ALAndrei L Lomize
Andrei L Lomize
IPIrina D Pogozheva
Irina D Pogozheva
MLMikhail A Lomize
Mikhail A Lomize
Henry  MosbergHenry Mosberg
Henry Mosberg
Three-dimensional (3D) structures of numerous peripheral membrane proteins have been determined. Biological activity, stability, and conformations of these proteins depend on their spatial positions with respect to the lipid bilayer. However, these positions are usually undetermined.

1 August 2005 in Biochemistry
Verified
Journal Article
Closed access
IPIrina D. Pogozheva
Irina D. Pogozheva
BCBiao-Xin Chai
Biao-Xin Chai
ALAndrei L. Lomize
Andrei L. Lomize
TFTung M. Fong
Tung M. Fong
DWDavid H. Weinberg
David H. Weinberg
Henry  MosbergHenry Mosberg
Henry Mosberg

1 November 2013 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
IPIrina D. Pogozheva
Irina D. Pogozheva
STStephanie Tristram-Nagle
Stephanie Tristram-Nagle
Henry  MosbergHenry Mosberg
Henry Mosberg
ALAndrei L. Lomize
Andrei L. Lomize

26 March 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
Henry  MosbergHenry Mosberg
Henry Mosberg
LYLarisa Yeomans
Larisa Yeomans
JAJessica P. Anand
Jessica P. Anand
VPVanessa Porter
Vanessa Porter
KSKatarzyna Sobczyk-Kojiro
Katarzyna Sobczyk-Kojiro
EJEmily M. Jutkiewicz
Emily M. Jutkiewicz
We have previously described a cyclic tetrapeptide, 1, that displays μ opioid receptor (MOPr) agonist and δ opioid receptor (DOPr) antagonist activity, a profile associated with a reduced incidence of opioid tolerance and dependence. Like many peptides, 1 has poor bioavailability. We describe here an analogue of 1 with an added C-terminal β-glucosylserine residue, Ser(β-Glc)NH2, a modification that has previously been shown to improve bioavailability of opioid peptides. The resulting peptide, 4, exhibits full antinociceptive efficacy in the mouse warm water tail withdrawal assay after intraperitoneal administration with potency similar to that of morphine. Further, 4 does not give rise to acute tolerance and thus represents a promising lead for the development of opioid analgesics with reduced side effects.

27 February 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Henry  MosbergHenry Mosberg
Henry Mosberg
LYLarisa Yeomans
Larisa Yeomans
AHAubrie A. Harland
Aubrie A. Harland
ABAaron M. Bender
Aaron M. Bender
KSKatarzyna Sobczyk-Kojiro
Katarzyna Sobczyk-Kojiro
JTJohn R. Traynor
John R. Traynor